A citation-based method for searching scientific literature

Mariela Glandt, Itamar Raz. J Obes 2011
Times Cited: 29







List of co-cited articles
86 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Multicenter, placebo-controlled trial of lorcaserin for weight management.
Steven R Smith, Neil J Weissman, Christen M Anderson, Matilde Sanchez, Emil Chuang, Scott Stubbe, Harold Bays, William R Shanahan. N Engl J Med 2010
537
27

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen, Michael E J Lean. Lancet 2009
563
17

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
W Philip T James, Ian D Caterson, Walmir Coutinho, Nick Finer, Luc F Van Gaal, Aldo P Maggioni, Christian Torp-Pedersen, Arya M Sharma, Gillian M Shepherd, Richard A Rode,[...]. N Engl J Med 2010
477
17

Meta-analysis: pharmacologic treatment of obesity.
Zhaoping Li, Margaret Maglione, Wenli Tu, Walter Mojica, David Arterburn, Lisa R Shugarman, Lara Hilton, Marika Suttorp, Vanessa Solomon, Paul G Shekelle,[...]. Ann Intern Med 2005
438
13


A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Meredith C Fidler, Matilde Sanchez, Brian Raether, Neil J Weissman, Steven R Smith, William R Shanahan, Christen M Anderson. J Clin Endocrinol Metab 2011
323
13

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
L J Aronne, S Tonstad, M Moreno, I Gantz, N Erondu, S Suryawanshi, C Molony, S Sieberts, J Nayee, A G Meehan,[...]. Int J Obes (Lond) 2010
51
13



Anti-obesity drugs: past, present and future.
R John Rodgers, Matthias H Tschöp, John P H Wilding. Dis Model Mech 2012
213
13

Is the GLP-1 system a viable therapeutic target for weight reduction?
Jenny Tong, Darleen A Sandoval. Rev Endocr Metab Disord 2011
13
23

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
Julio Rosenstock, Leslie J Klaff, Sherwyn Schwartz, Justin Northrup, John H Holcombe, Kenneth Wilhelm, Michael Trautmann. Diabetes Care 2010
135
10

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
J Proietto, A Rissanen, J B Harp, N Erondu, Q Yu, S Suryawanshi, M E Jones, A O Johnson-Levonas, S B Heymsfield, K D Kaufman,[...]. Int J Obes (Lond) 2010
46
10

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
M H Davidson, J Hauptman, M DiGirolamo, J P Foreyt, C H Halsted, D Heber, D C Heimburger, C P Lucas, D C Robbins, J Chung,[...]. JAMA 1999
529
10

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Jean-Pierre Després, Alain Golay, Lars Sjöström. N Engl J Med 2005
873
10

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.
Diana Rucker, Raj Padwal, Stephanie K Li, Cintia Curioni, David C W Lau. BMJ 2007
429
10

Valvular heart disease associated with fenfluramine-phentermine.
H M Connolly, J L Crary, M D McGoon, D D Hensrud, B S Edwards, W D Edwards, H V Schaff. N Engl J Med 1997
874
10


Pharmacotherapies for obesity: past, current, and future therapies.
Lisa L Ioannides-Demos, Loretta Piccenna, John J McNeil. J Obes 2011
105
10

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
A Astrup, R Carraro, N Finer, A Harper, M Kunesova, M E J Lean, L Niskanen, M F Rasmussen, A Rissanen, S Rössner,[...]. Int J Obes (Lond) 2012
323
10


Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
A Avenell, J Broom, T J Brown, A Poobalan, L Aucott, S C Stearns, W C S Smith, R T Jung, M K Campbell, A M Grant. Health Technol Assess 2004
383
10

Anti-Obesity Drugs: A Review about Their Effects and Safety.
Jun Goo Kang, Cheol-Young Park. Diabetes Metab J 2012
230
10

Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.
G Valsamakis, P G McTernan, R Chetty, N Al Daghri, A Field, W Hanif, A H Barnett, S Kumar. Metabolism 2004
125
6

Long-term weight-loss maintenance: a meta-analysis of US studies.
J W Anderson, E C Konz, R C Frederich, C L Wood. Am J Clin Nutr 2001
582
6

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
L Blonde, E J Klein, J Han, B Zhang, S M Mac, T H Poon, K L Taylor, M E Trautmann, D D Kim, D M Kendall. Diabetes Obes Metab 2006
291
6

Obesity, insulin resistance, and cardiovascular disease.
Gerald Reaven, Fahim Abbasi, Tracey McLaughlin. Recent Prog Horm Res 2004
184
6

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
391
6

Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
Christian Torp-Pedersen, Ian Caterson, Walmir Coutinho, Nick Finer, Luc Van Gaal, Aldo Maggioni, Arya Sharma, Wygenia Brisco, Roger Deaton, Gillian Shepherd,[...]. Eur Heart J 2007
76
6


Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
Peter Kopelman, Gerrit de H Groot, Aila Rissanen, Stephan Rossner, Soren Toubro, Richard Palmer, Rob Hallam, Andrew Bryson, Roger I Hickling. Obesity (Silver Spring) 2010
53
6

Long-term pharmacotherapy for obesity and overweight.
R Padwal, S K Li, D C W Lau. Cochrane Database Syst Rev 2004
138
6

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Thomas A Wadden, John P Foreyt, Gary D Foster, James O Hill, Samuel Klein, Patrick M O'Neil, Michael G Perri, F Xavier Pi-Sunyer, Cheryl L Rock, Janelle S Erickson,[...]. Obesity (Silver Spring) 2011
237
6

Safety of drug therapies used for weight loss and treatment of obesity.
Lisa L Ioannides-Demos, Joseph Proietto, Andrew M Tonkin, John J McNeil. Drug Saf 2006
81
6

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
450
6

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
6

Anti-obesity drugs: a review about their effects and their safety.
Giuseppe Derosa, Pamela Maffioli. Expert Opin Drug Saf 2012
96
6

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden. Am J Clin Nutr 2012
296
6

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
David B Allison, Kishore M Gadde, William Timothy Garvey, Craig A Peterson, Michael L Schwiers, Thomas Najarian, Peter Y Tam, Barbara Troupin, Wesley W Day. Obesity (Silver Spring) 2012
279
6

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N Engl J Med 2002
6

Influence of topiramate in the regulation of energy balance.
D Richard, J Ferland, J Lalonde, P Samson, Y Deshaies. Nutrition 2000
96
6

Orlistat in the long-term treatment of obesity in primary care settings.
J Hauptman, C Lucas, M N Boldrin, H Collins, K R Segal. Arch Fam Med 2000
197
6



The FDA's assessment of two drugs for chronic weight management.
Eric Colman, Julie Golden, Mary Roberts, Amy Egan, Joyce Weaver, Curtis Rosebraugh. N Engl J Med 2012
104
6

Pharmacological management of appetite expression in obesity.
Jason C G Halford, Emma J Boyland, John E Blundell, Tim C Kirkham, Joanne A Harrold. Nat Rev Endocrinol 2010
82
6

Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Talib A Hussain, Thazhumpal C Mathew, Ali A Dashti, Sami Asfar, Naji Al-Zaid, Hussein M Dashti. Nutrition 2012
102
6

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.
Katherine M Flegal, Margaret D Carroll, Brian K Kit, Cynthia L Ogden. JAMA 2012
6

A double-blind randomized placebo-controlled trial of sibutramine.
G A Bray, D H Ryan, D Gordon, S Heidingsfelder, F Cerise, K Wilson. Obes Res 1996
107
6

Bariatric surgery and long-term cardiovascular events.
Lars Sjöström, Markku Peltonen, Peter Jacobson, C David Sjöström, Kristjan Karason, Hans Wedel, Sofie Ahlin, Åsa Anveden, Calle Bengtsson, Gerd Bergmark,[...]. JAMA 2012
839
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.